NCT01145989View on ClinicalTrials.gov

A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 15, 2011

Primary Completion Date

October 29, 2014

Study Completion Date

November 27, 2015

Conditions
Multiple Myeloma
Interventions
DRUG

AT9283

Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks

Trial Locations (6)

T2N 4N2

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

E2L 4L2

Atlantic Health Sciences Corporation, Saint John

B3H 1V7

QEII Health Sciences Center, Halifax

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto

Sponsors
All Listed Sponsors
collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

lead

NCIC Clinical Trials Group

NETWORK